Project Grant R35GM156307

Award Date 5/1/25
Completion Date 4/30/30
Dollars Obligated $423K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
The National Institute of General Medical Sciences (NIGMS) awarded a $395,881 project grant (CFDA 93.859 - Biomedical Research and Research Training) to Vanderbilt University to conduct research on developing new protocols for altering the molecular topology of biologically active natural products and therapeutic compounds. The grant aims to enable access to previously inaccessible chemical space and potentially improve the biological properties of clinical candidates. Key proposed activities...
This $1,542,569 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of new copper-catalyzed reactions for the stereoselective synthesis of chiral amine and ether derivatives, including saturated heterocycles. The objectives include exploring reactions that propagate chirality initiated by enantioselective copper-catalysis, developing a new synthesis of enantioenriched oxygen...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is funding research to engineer "promiscuous enzymes" that can catalyze new-to-nature chemical reactions to produce non-canonical amino acids. The $800,308 award to the University of Wisconsin-Madison aims to develop mechanistic understanding and directed evolution strategies to engineer these highly selective enzymes, which can enable...
The National Institute of General Medical Sciences (NIGMS) has awarded a $385,298 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Stony Brook University, a prominent research institution, to develop new methods for synthesizing complex primary amines from simple amino acids. The overarching 5-year goal is to establish a novel biomimetic organic synthesis approach that leverages rationally designed pyridoxal-5'-phosphate (PLP)-mimicking catalysts to enable open-shell...
This $146,816 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of novel peptide catalysts for stereo- and site-selective carbon-carbon bond formation reactions. The project leverages automated fast-flow peptide synthesis and machine learning to access a broad chemical space of mid-length peptide catalysts containing non-natural amino acids. One research direction focuses on...
The National Institute of General Medical Sciences (NIGMS) awarded a $390,000 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the University of Texas at Dallas. The grant, which runs from August 1, 2024 to May 31, 2029, supports the development of new chemical methods and synthesis strategies to enable reliable access to complex bioactive natural and unnatural compounds. This research aims to advance the synthesis of polycyclic molecular frameworks with...
The National Institute of General Medical Sciences (NIGMS) awarded a $358,012 Project Grant (CFDA 93.859 Biomedical Research and Research Training) to the Massachusetts Institute of Technology (MIT) to support research on developing a new stereochemical editing strategy for creating quaternary stereocenters. The objective is to establish a dual asymmetric photoredox/nickel catalysis system and explore the use of chiral counteranions to precisely control the stereochemistry of these complex...
This $360,100 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) supports research to develop new pharmaceutical synthetic methods through supramolecular catalysis. The Principal Investigator at the University of California, Berkeley will leverage pioneering work in supramolecular hosts and transition metal catalysis to enable transformations relevant to drug discovery, including...
This Project Grant award of $371,371.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development and application of reactions to enable molecular rigidification. The award will fund a research program focused on developing reactions to access rigid small and medium-sized strained rings, using sulfone anions as carbene surrogates and new methods to stabilize reactive alkylidene units through...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $146,816 to support research on the biocatalytic synthesis of N-N and C-N heterobiaryl atropisomers. The principal investigator, based at the Regents of the University of Michigan, will employ bioinformatic techniques to develop a library of flavin-dependent aromatic hydroxylase (FDAH) enzymes to explore their unique coupling reactivity...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $422,569 to Vanderbilt University for the development of new chemical reactions and reagents to generate enantioenriched organic compounds. The overarching goal is to enable the concise synthesis of secondary amines, tertiary amines, and vicinal diamines as single stereoisomers, which are valuable precursors for small molecule therapeutic agents and biologically active natural products. The proposed methods involve the use of bis(amidine) reagents that form chiral proton complexes, as well as the exploration of a new catalyst design using achiral Brønsted acid activators. The project aims to develop innovative multicomponent coupling reactions that leverage chiral proton catalysis to control enantioselectivity, with the potential to impact small molecule synthesis and therapeutic agent development. This 5-year project is set to begin on May 1, 2025 and conclude on April 30, 2030.

Generated 5/13/25, 3:43 AM